| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
2 companies
Daniel Tasse is Director at RGNX, with reported holdings spanning 2 companies. Daniel Tasse's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $393K at current prices.
Daniel Tasse's largest disclosed position is in RGNX as Director, worth about $220K.
Daniel Tasse has 17 Form 4 filings on record from August 2016 to May 2026, across 2 companies: Director at Regenxbio (RGNX), 2016–2026; Chief Executive Officer at DBV Technologies (DBVT), 2021–2025.
The 22 reported transactions were 16 option or other derivative awards, 5 stock awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $14K and no sales.
The only open-market purchase was 17,094 shares of DBVT at an average $0.83 on March 8, 2024, about $14K. Twelve months later DBVT was down 51%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 8, 2024 | DBVT Dbv Technologies S.A. | Chief Executive Officer | Buy | 17,094 | $0.83 | $14,188.02 | New | -33.9% | -51.3% |